Delivery Order SPE2DB25D3306-SPE2DB25FUCXH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on August 28, 2025, with completion anticipated by September 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for Benlysta 200 mg/ml auto-injector with a ceiling value of $9,248.01. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the company's existing contract vehicle. The order is scheduled for completion by September 24, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania location. Benlysta (belimumab) is a biologic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 21, 2025, with completion scheduled for September 12, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody immunosuppressant medication used primarily to treat systemic lupus...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injector on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCXHDelivery Order
The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on September 8, 2025, with completion targeted for September 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and lupus nephritis, representing a specialized biologic pharmaceutical requiring careful handling and distribution through established medical supply channels. This delivery order operates under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen leverages this comprehensive prime contract vehicle to supply medications, vaccines, medical devices, and specialized healthcare commodities to military healthcare systems, the Defense Health Agency, and other government healthcare entities globally. The company's extensive portfolio of federal pharmaceutical contracts demonstrates its established capability to fulfill complex medical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 9/8/25 |